Form 8-K - Current report:
SEC Accession No. 0001193125-23-147049
Filing Date
2023-05-17
Accepted
2023-05-17 16:31:09
Documents
20
Period of Report
2023-05-17
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d436124d8k.htm   iXBRL 8-K 35417
2 EX-4.1 d436124dex41.htm EX-4.1 80922
3 EX-4.2 d436124dex42.htm EX-4.2 82453
4 EX-4.3 d436124dex43.htm EX-4.3 72328
5 EX-4.4 d436124dex44.htm EX-4.4 80362
6 EX-4.5 d436124dex45.htm EX-4.5 71469
7 EX-4.6 d436124dex46.htm EX-4.6 81921
8 EX-5.1 d436124dex51.htm EX-5.1 8905
  Complete submission text file 0001193125-23-147049.txt   800178

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA mrk-20230517.xsd EX-101.SCH 4682
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE mrk-20230517_def.xml EX-101.DEF 14269
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrk-20230517_lab.xml EX-101.LAB 23991
12 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrk-20230517_pre.xml EX-101.PRE 15366
14 EXTRACTED XBRL INSTANCE DOCUMENT d436124d8k_htm.xml XML 8334
Mailing Address 2000 GALLOPING HILL ROAD KENILWORTH NJ 07033
Business Address 2000 GALLOPING HILL ROAD KENILWORTH NJ 07033 908-740-4000
Merck & Co., Inc. (Filer) CIK: 0000310158 (see all company filings)

EIN.: 221918501 | State of Incorp.: NJ | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-06571 | Film No.: 23932201
SIC: 2834 Pharmaceutical Preparations